Core Insights - JD Health has launched the exclusive online debut of Bo You Ping (Dulaglutide Injection), a biosimilar for Trulicity, aimed at controlling blood sugar in adults with type 2 diabetes [1][2] - The product is the first and only approved biosimilar of Dulaglutide globally, addressing the growing diabetes prevalence in China, which exceeds 223 million patients [1][2] Company Developments - JD Health partnered with Shanghai Pharmaceuticals to promote Bo You Ping across all channels in mainland China, enhancing its market presence [2] - The collaboration aims to leverage JD Health's established online launch solutions and robust supply chain capabilities to facilitate patient access to innovative treatments [2] Industry Context - Type 2 diabetes is the most common form of diabetes, with traditional treatments facing challenges such as high medication frequency and risks of hypoglycemia [1] - GLP-1 receptor agonists, like Dulaglutide, are recommended for their significant blood sugar-lowering effects, weight loss benefits, and cardiovascular and renal protection [2]

Core Viewpoint - The stock of Boan Biotechnology (06955) fell over 8% following the release of its interim results, indicating market concerns regarding its profitability despite revenue growth [1] Financial Performance - For the first half of the year, Boan Biotechnology reported revenue of RMB 393 million, an increase of 8.4% year-on-year [1] - Gross profit remained stable at RMB 283 million, showing no significant change compared to the previous year [1] - The profit attributable to the parent company was RMB 20.514 million, a decrease of 66.7% year-on-year [1] Product Sales - The increase in revenue was primarily driven by the sales of products (Boan's You Nuo, Boan's You Bei, and Bo Luo Jia), which grew by 15.9% to RMB 385.3 million for the six months ending June 30, 2024 [1] Regulatory Approval - On August 9, Boan Biotechnology announced that its self-developed product, Boan You Ping (Dulaglutide injection), received approval from the National Medical Products Administration for market launch [1] - This product is the world's first and currently the only approved biosimilar to Trulicity, with no other domestic Dulaglutide injections having entered the market approval application stage [1] - The commercialization of Boan You Ping in mainland China will be conducted in collaboration with Shanghai Pharmaceuticals Holding Co., Ltd. [1]